Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

This publication has 25 references indexed in Scilit:

• A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
  Annals of Oncology, 2006
• Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement
  Supportive Care in Cancer, 2004
• Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist
  Cancer, 2003
• Measuring chemotherapy‐induced nausea and emesis
  Cancer, 2003
• Clinical Science Review: Comparative Review of 5-HT₃Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting
  Cancer Investigation, 2000
• An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting
  European Journal Of Cancer, 1997
• On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993
  Annals of Oncology, 1996
• Quality of Life Studies in Chemotherapy-Induced Emesis
  Oncology, 1996
• Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting
  Annals of Internal Medicine, 1990
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990